These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 15915059

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b.
    Brandberg Y, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J.
    Eur J Cancer; 2012 Sep; 48(13):2012-9. PubMed ID: 22196968
    [Abstract] [Full Text] [Related]

  • 4. Patient preferences for adjuvant interferon alfa-2b treatment.
    Kilbridge KL, Weeks JC, Sober AJ, Haluska FG, Slingluff CL, Atkins MB, Sock DE, Kirkwood JM, Nease RF.
    J Clin Oncol; 2001 Feb 01; 19(3):812-23. PubMed ID: 11157035
    [Abstract] [Full Text] [Related]

  • 5. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
    Bramlette TB, Lawson DH, Washington CV, Veledar E, Johns BR, Brisman SF, Abramova L, Chen SC.
    Dermatol Surg; 2007 Jan 01; 33(1):11-6. PubMed ID: 17214673
    [Abstract] [Full Text] [Related]

  • 6. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
    Yamazaki N, Uhara H, Wada H, Matsuda K, Yamamoto K, Shimamoto T, Kiyohara Y.
    J Dermatol; 2016 Oct 01; 43(10):1146-1153. PubMed ID: 27087489
    [Abstract] [Full Text] [Related]

  • 7. Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy.
    Kaehler KC, Blome C, Forschner A, Gutzmer R, Haalck T, Heinzerling L, Kornek T, Livingstone E, Loquai C, Maul LV, Lang BM, Schadendorf D, Stade B, Terheyden P, Utikal J, Wagner T, Hauschild A, Garbe C, Augustin M.
    Medicine (Baltimore); 2016 Nov 01; 95(46):e5375. PubMed ID: 27861370
    [Abstract] [Full Text] [Related]

  • 8. Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma.
    Mohr P, Hauschild A, Trefzer U, Weichenthal M.
    J Clin Oncol; 2009 Aug 20; 27(24):e70; author reply e71. PubMed ID: 19620476
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A retrospective analysis of tolerance and outcomes of cutaneous malignant melanoma in patients receiving adjuvant interferon-alpha 2B: a community oncology perspective.
    Afzal MZ, Pinnamaneni V, Birendra KC, Davis AT, Koehler TJ, Lakhani N.
    J Exp Ther Oncol; 2017 Sep 20; 11(2):91-96. PubMed ID: 28976130
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
    Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caracò C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N.
    J Transl Med; 2010 Aug 16; 8():76. PubMed ID: 20712892
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
    Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG.
    Cancer J; 2000 Aug 16; 6(3):139-45. PubMed ID: 10882328
    [Abstract] [Full Text] [Related]

  • 20. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].
    Chiarion-Sileni V, Del Bianco P, Romanini A, Guida M, Paccagnella A, Dalla Palma M, Naglieri E, Ridolfi R, Silvestri B, Michiara M, De Salvo GL.
    BMC Cancer; 2006 Feb 27; 6():44. PubMed ID: 16504154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.